Mastek Ltd Q2 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/fbkkauaxrzk4zwyjh55eli6h.pdf

Key Takeaways


Revenue Performance & Regional Dynamics

Hiral Chandrana: "We've crossed USD 100 million run rate as a combined U.S. business for the first time in Mastek after many years. And so we believe from here on, there should be more positive momentum."

Margin Walk & Recovery Path

Arun Agarwal: "Let us get into 17% to 19% range first, Mohit, and definitely, our endeavor will be to further up it and keep it more closer to 19%. But let us first come back to that range."

Marquee Wins & Account Mining


BizAnalytica Acquisition


Demand Environment & Headwinds

Hiral Chandrana: "customers are continuing to look at cost consolidation as well as now evaluating how Generative AI is going to play a role in their future. So we see that as a potential opportunity for us to look at, maybe even looking at upsetting some of the incumbents, some of the larger incumbents. But that's too early to tell."

People & Attrition

Hiral Chandrana: "the skills are definitely much more niche as well as specialized in some cases. So that is clearly talent that is much more in demand. And that's one of the reasons why we want to make sure we do the right thing for our employees who have contributed to the growth and make sure that they are rewarded."

Guidance & Commitments

CommitmentSpecificsTimeline
EBITDA margin recoveryReturn to 17% to 19% range through operating levers (grade mix, pyramid, subcontractor conversion, utilization)Coming quarters
U.K. revenue growthGrowth driven by strong order booking and deal momentumQ4 FY24
U.S. margin targetFirst reach double-digit margin in geography, then closer to company average with 2-3% delta acceptableSteady state in 2-3 quarters
BizAnalytica marginReturn to double-digit marginEnd of this year
BizAnalytica marginCloser to Mastek margin profileNext year
Decision delaysGeneral delays in client decisions will persistAt least next 1-2 quarters
NHS revenueNo major incremental growth; deals and order book may set stage for stronger FY25Q3/Q4 FY24
U.K. government expansionExpand purview into new departments (Environment/Food & Rural Affairs, Cabinet Office, police protection)Next 2-3 years
U.S. healthcare verticalReach USD 100 million vertical sizeNext 3-4 years

Key Metrics

MetricQ2 FY24
Revenue₹766 cr, +5.6% QoQ and +22.4% YoY
Constant currency revenue growth+4.4% QoQ, +13.5% YoY
US dollar revenue growth+18.6% YoY
Organic revenue growth (INR)+2.7% QoQ, excluding BizAnalytica
US business organic growth (constant currency)+5% QoQ, excluding BizAnalytica
Operating EBITDA margin16.1%, down 140 bps QoQ; wage hikes impact of 130–140 bps and BizAnalytica dilution of 30–40 bps
PAT₹65.3 cr, vs ₹73.5 cr in Q1 FY24
12-month order backlog growth (INR)+5.6% QoQ, +22.3% YoY
12-month order backlog growth (constant currency)+13.4% YoY
Headcount5,598, marginal increase QoQ including BizAnalytica colleagues
Utilization82.5%, excluding leaves 84.1%
Gross cash₹312 cr, vs ₹220 cr in Q1 FY24
Borrowings₹477 cr as of 30 September
Clients added29 during the quarter
US business run rateCrossed $100 million for the first time